Search

Your search keyword '"Maes, Michael"' showing total 664 results

Search Constraints

Start Over You searched for: Author "Maes, Michael" Remove constraint Author: "Maes, Michael" Database MEDLINE Remove constraint Database: MEDLINE
664 results on '"Maes, Michael"'

Search Results

1. T helper-1 activation via interleukin-16 is a key phenomenon in the acute phase of severe, first-episode major depressive disorder and suicidal behaviors.

2. T cell activation and lowered T regulatory cell numbers are key processes in severe major depressive disorder: Effects of recurrence of illness and adverse childhood experiences.

3. Cytokine dysregulation in amnestic mild cognitive impairment.

4. Collaborative outcomes study on health and functioning during infection times (COH-FIT): Insights on modifiable and non-modifiable risk and protective factors for wellbeing and mental health during the COVID-19 pandemic from multivariable and network analyses.

5. The effects of the MTHFR 677C>T (rs1801133) genetic variant on susceptibility and disability worsening in multiple sclerosis patients are mediated by homocysteine.

6. Sweat-based stress screening with gas chromatography-ion mobility spectrometry and electronic nose.

7. The recurrence of illness (ROI) index is a key factor in major depression that indicates increasing immune-linked neurotoxicity and vulnerability to suicidal behaviors.

8. Increased malondialdehyde and nitric oxide formation, lowered total radical trapping capacity coupled with psychological stressors are strongly associated with the phenome of first-episode mild depression in undergraduate students.

9. Neurocognitive Features of Mild Cognitive Impairment and Distress Symptoms in Older Adults Without Major Depression.

10. The Antidepressant- and Anxiolytic-Like Effects of the Phosphodiesterase Type-5 Inhibitor Tadalafil are Associated with the Modulation of the Gut-Brain Axis During CNS Autoimmunity.

11. The novel schizophrenia subgroup "major neurocognitive psychosis" is validated as a distinct class through the analysis of immune-linked neurotoxicity biomarkers and neurocognitive deficits.

12. Diagnostic value of structural, functional and effective connectivity in bipolar disorder.

13. From human herpes virus-6 reactivation to autoimmune reactivity against tight junctions and neuronal antigens, to inflammation, depression, and chronic fatigue syndrome due to Long COVID.

14. A further examination of growth factors, T helper 1 polarization, and the gut microbiome in major depression: Associations with reoccurrence of illness, cognitive functions, suicidal behaviors, and quality of life.

15. Immune activation and immune-associated neurotoxicity in Long-COVID: A systematic review and meta-analysis of 103 studies comprising 58 cytokines/chemokines/growth factors.

16. Reactivation of herpesvirus type 6 and IgA/IgM-mediated responses to activin-A underpin long COVID, including affective symptoms and chronic fatigue syndrome.

17. Construction of a short version of the Montreal Cognitive Assessment (MoCA) rating scale for the Thai population using Partial Least Squares analysis.

18. Complex Intersections Between Adverse Childhood Experiences and Negative Life Events Impact the Phenome of Major Depression.

19. Global and risk-group stratified well-being and mental health during the COVID-19 pandemic in adults: Results from the international COH-FIT Study.

20. T cell activation and deficits in T regulatory cells are associated with major depressive disorder and severity of depression.

21. The mast cells - Cytokines axis in Autism Spectrum Disorder.

22. Effects of antidepressant on FKBP51 mRNA expression and neuroendocrine hormones in patients with panic disorder.

23. Towards a major methodological shift in depression research by assessing continuous scores of recurrence of illness, lifetime and current suicidal behaviors and phenome features.

24. Adverse childhood experiences and recent negative events are associated with activated immune and growth factor pathways, the phenome of first episode major depression and suicidal behaviors.

25. In major dysmood disorder, physiosomatic, chronic fatigue and fibromyalgia symptoms are driven by immune activation and increased immune-associated neurotoxicity.

26. Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline Treatment.

27. Mast Cells in Autism Spectrum Disorder-The Enigma to Be Solved?

28. Predictors of increased affective symptoms and suicidal ideation during the COVID-19 pandemic: results from a large-scale study of 14 271 Thai adults.

29. Neuronal damage and inflammatory biomarkers are associated with the affective and chronic fatigue-like symptoms due to end-stage renal disease.

30. Increased IgA-mediated responses to the gut paracellular pathway and blood-brain barrier proteins predict delirium due to hip fracture in older adults.

31. Protective effects of IL18-105G > A and IL18-137C > Ggenetic variants on severity of COVID-19.

32. Distress Symptoms of Old Age and Mild Cognitive Impairment are Two Distinct Dimensions in Older Adults Without Major Depression.

33. The General Neurocognitive Decline in Patients with Methamphetamine Use and Transient Methamphetamine-induced Psychosis is Primarily Determined by Oxidative and AGE-RAGE Stress.

34. The Gold Standard Diagnosis of Schizophrenia is Counterproductive: Towards Quantitative Research and Diagnostic Algorithmic Rules (RADAR) and their Derived Qualitative Distinct Classes.

35. Comprehensive immunoprofiling of neurodevelopmental disorders suggests three distinct classes based on increased neurogenesis, Th-1 polarization or IL-1 signaling.

36. Brooding and neuroticism are strongly interrelated manifestations of the phenome of depression.

37. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019.

38. The tryptophan catabolite or kynurenine pathway in autism spectrum disorder; a systematic review and meta-analysis.

39. Adverse childhood experiences and reoccurrence of illness impact the gut microbiome, which affects suicidal behaviours and the phenome of major depression: towards enterotypic phenotypes.

40. Neuropsychiatric disturbances in mild cognitive impairment: A scientometric analysis.

41. Methamphetamine (MA) use and MA-induced psychosis are associated with increasing aberrations in the compensatory immunoregulatory system, interleukin-1α, and CCL5 levels.

42. Increased AGE-RAGE axis stress in methamphetamine abuse and methamphetamine-induced psychosis: Associations with oxidative stress and increased atherogenicity.

43. Reverse cholesterol transport and lipid peroxidation biomarkers in major depression and bipolar disorder: A systematic review and meta-analysis.

44. Anxiety due to Long COVID is partially driven by activation of the tryptophan catabolite (TRYCAT) pathway.

45. Role of T and B lymphocyte cannabinoid type 1 and 2 receptors in major depression and suicidal behaviours.

46. Paraoxonase 1 status is a major Janus-faced component of mild and moderate acute ischemic stroke and consequent disabilities.

47. Immunoinflammatory and oxidative alterations in subjects with schizophrenia under clozapine: A meta-analysis.

49. Cognitive impairments predict the behavioral and psychological symptoms of dementia.

50. Lower Nerve Growth Factor Levels in Major Depression and Suicidal Behaviors: Effects of Adverse Childhood Experiences and Recurrence of Illness.

Catalog

Books, media, physical & digital resources